MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research to evaluate several intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Main demo aims were to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though among the exploratory goa... https://martinaumew.idblogmaker.com/30250411/everything-about-tyrosinase-in-12